Corcept Therapeutics Incorporated (CORT)
NASDAQ: CORT · IEX Real-Time Price · USD
+0.55 (2.00%)
At close: May 17, 2024, 4:00 PM
+0.19 (0.68%)
After-hours: May 17, 2024, 5:18 PM EDT

Company Description

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States.

It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.

The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors.

In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial.

The company was incorporated in 1998 and is headquartered in Menlo Park, California.

Corcept Therapeutics Incorporated
Corcept Therapeutics logo
Country United States
Founded 1998
Industry Biotechnology
Sector Healthcare
Employees 352
CEO Dr. Joseph K. Belanoff M.D.

Contact Details

149 Commonwealth Drive
Menlo Park, California 94025
United States
Phone 650.688.8803

Stock Details

Ticker Symbol CORT
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001088856
CUSIP Number 218352102
ISIN Number US2183521028
Employer ID 77-0487658
SIC Code 2834

Key Executives

Name Position
Dr. Joseph K. Belanoff M.D. Co-Founder, President, Chief Executive Officer and Director
Atabak Mokari Chief Financial Officer and Treasurer
Dr. Hazel Hunt Ph.D. Chief Scientific Officer
Sean Maduck President of Endocrinology
Gary Charles Robb Chief Business Officer and Secretary
Joseph Douglas Lyon Chief Accounting and Technology Officer
Amy Flood Chief Human Resources and Communications Officer
Dr. William Guyer Pharm.D. Chief Development Officer
Monica Tellado President of Emerging Markets
Roberto W. Vieira President of Oncology

Latest SEC Filings

Date Type Title
May 13, 2024 144 Filing
May 9, 2024 144 Filing
May 1, 2024 10-Q Quarterly Report
May 1, 2024 8-K Current Report
May 1, 2024 144 Filing
Apr 18, 2024 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 17, 2024 ARS Filing
Apr 17, 2024 8-K Current Report
Apr 10, 2024 DEF 14A Other definitive proxy statements
Apr 4, 2024 144 Filing